Targeting Cancer Cells Through Dual Recognition: AbbVie Pays $40 Million to Partner with DISCO
This solid tumor collaboration focuses on bispecific therapies that recognize paired surface proteins simultaneously. Potential subsequent payments total up to $2.5 billion, but the research remains at the drug discovery stage, with no clinical evidence yet that it can reduce damage to normal tissue.